ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 25, 2021 16:01 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and...
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
October 22, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
October 21, 2021 09:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Proposed Public Offering of Common Stock
October 20, 2021 16:01 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference
October 19, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.
October 18, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (RSV) Presented at IDWeek 2021
October 04, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021
October 01, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics to Virtually Participate in the Cantor Healthcare Conference
September 23, 2021 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations
September 08, 2021 07:00 ET
|
ADMA Biologics, Inc.
Expected to Provide Improved Gross Margins, Enhanced Patient Supply Consistency, Accelerated Inventory Production Cycle Time and Increased Control and Visibility of Commercial Product Lot Releases ...